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Abstract
Background: A new monogenic neurodegenerative disease affecting ribosomal metabolism has recently been
identified in association with a monoallelic UBTF putative gain of function variant (NM_001076683.1:c.628G>A,
hg19). Phenotype is consistent among these probands with progressive motor, cognitive, and behavioural
regression in early to middle childhood.
Case presentation: We report on a child with this monoallelic UBTF variant who presented with progressive
disease including regression, episodes of subacute deterioration during febrile illnesses and a remarkable EEG
pattern with a transient pattern of semi-periodic slow waves.
Conclusions: This case further supports the phenotype-genotype correlation of neurodegeneration associated with
UBTF c.628G>A. Moreover, it brings new insights into the clinical features and EEG that could possibly serve as
diagnostic markers of this otherwise nonspecific phenotype.
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Background
Recently three independent teams [1–3] reported on a
new monogenic neurodegenerative disease of childhood
associated with a specific monoallelic de novo c.628G>A
(p.Glu210Lys) UBTF variant. Together, 12 male and fe-
male patients aged 6 to 33 years old were described with
a consistent phenotype of normal or close to normal
early developmental milestones followed by motor and
cognitive regression [1–3].
UBTF (Upstream Binding Transcription Factor, OMIM
*600673) gene codes for Upstream Binding Factor
(UBF), a protein that acts as a transcription factor for
RNA polymerase I, essential for the generation of ribo-
somal RNA transcripts (rRNA) from ribosomal DNA
(rDNA) in the nucleolus [1, 2]. The c.628G>A variant
confers a gain of function to the protein resulting in in-
creased expression of rDNA and rRNA, which in turn is
thought to lead to scavenging of RNA binding proteins,
altered RNA disposal machinery and ribosome biogen-
esis [1], as well as defective DNA damage repair and
chromatid cohesion [1, 2, 4, 5].
We describe a further case of childhood neurodegenera-
tion associated with this UBTF variant and add new in-
sights on clinical evolution and electro-encephalographic
features.
Case presentation
This 12-year-old boy was referred at 5 years of age for
developmental delay (Fig. 1). He was the first child of
unrelated sri-lankan parents; two younger siblings were
healthy. His medical history was unremarkable and de-
velopmental milestones were normal up to 2 years of
age, when parents noted speech and expressive lan-
guage difficulties, frequent falls, and slowing of devel-
opmental progress without plateauing or loss of skills.
At presentation, head circumference was at 10-25th
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centile, height at 75-90th and weight at 25th. On clinical
examination, organomegaly or dysmorphic signs were
absent. There was mild hypotonia with ataxia of limbs
and gait ; cranial nerves and deep tendon reflexes
(DTR) were normal. Development was globally delayed.
Ten months later, following a febrile illness, the boy
presented with alternating periods of agitation and ap-
athy, loss of sphincter control, expressive and receptive
language regression and worsening of the cerebellar
syndrome. Three similar episodes occurred between
age 6 and 8 years, all triggered by benign infectious ill-
nesses. Thereafter, he displayed a downhill course with
progressive deterioration. At the age of 11 years he de-
veloped brief epileptic behaviour arrests. At 12 years
old, he has a severe intellectual disability (ID) and is
nonverbal but retains a friendly behaviour. He is unable
to walk unassisted and has swallowing difficulties. He
has a cerebellar syndrome with mild limb dystonia and
choreic movements, brisk DTR without other pyram-
idal signs.
A first brain magnetic resonance imaging (MRI) done at
5 yo, prior to regression, showed mild white matter atro-
phy and periventricular hyperintensities on T2-weighted
(T2W) images (Fig. 2). Follow-up MRIs done at age 6, 7
and 9 years showed progressive cortico-subcortical supra-
tentorial atrophy, periventricular and peritrigonal deep
white matter T2 hyperintensities (Fig. 2) with an increased
apparent diffusion coefficient. Cerebellum appeared mildly
atrophic at 9 yo.
A first electroencephalogram (EEG) done at 5 yo
(Fig. 3a) showed bilateral fronto-central spike and
spike-wave (SW) complexes during drowsiness and
sleep stage I with slightly slow background rhythm
for age (7-8Hz). From 7 to 9 yo, 2 EEGs showed a
pattern of semi-periodic diffuse slow delta waves
complexes occurring every 2 to 5 seconds (0.2-
0.3Hz) during wakefulness without clinical correlate
(Fig. 3b). Sleep EEG kept on showing frequent anter-
ior spike and SW complexes that became diffuse
from 9 yo (Fig. 3c). Electroclinical seizures were re-
corded at 11 yo, with diffuse alpha rhythmic dis-
charges at 11Hz during 10 seconds correlating with
behavioural arrest. Photosensitivity was never elicited
(minimum frequency 1 Hz). Visual and auditory
evoked potentials were normal.
A first cerebral-spinal fluid (CSF) analysis during the
first episode of regression at age 6 years showed 5 lym-
phocytes/mm3 and normal lactate, glucose and proteins
levels. Two subsequent spinal taps at age 7 years were
normal. Extensive workup including ammonium, lactate,
organic acids, amino-acids, acylcarnitines profile, lyso-
somal enzymes activities, anti-neuronal antibodies (CSF
and serum), anti-measles and anti-rubella antibodies
(serum and CSF), prion and interferon signature were all
negative.
At first, an Array Comparative Genomics Hybridisa-
tion (Agilent oligoNT array CGH 180K) was undertaken
and did not reveal any pathogenic change. Whole Exome
Fig. 1 Time course of the disease. Diagram illustrating time course of disease in our patient. Dotted grey line: normal developmental trajectory;
Red Line: developmental trajectory in our patient; Blue boxes: main signs and symptoms; Orange box: highlights period of subacute deterioration
possibly triggered by infection
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Sequencing was then performed on Illumina HiSeq2500
sequencer, with Agilent Sure Select XT Human All Exon
V5 capture kit, after appropriate informed consent. The
raw data from Whole Exome Sequencing (WES) were
screened using an in-house pipeline as previously de-
scribed [6] allowing for filtering of synonymous and
common variants to which a panel of approximately
1300 genes known to be implicated in developmental
delay and seizure disorders was applied. The original
analysis failed to yield any variant that might be plaus-
ibly linked to an intellectual disability or epilepsy pheno-
type [7]. The data were reanalyzed six months later
using an updated panel that (at that point) contained the
gene UBTF, that had just been published in connection
with an intellectual disability phenotype by Edvardson
et al [1]. This allowed for the detection of a heterozy-
gous c.628G>A UBTF variant, which was confirmed by
Sanger sequencing and found to be de novo.
Literature Review
The literature search yielded two case series and a
case report of patients carrying the same de novo het-
erozygous c.628G>A UBTF variant [1–3]. Results are
summarised in Table 1. Median age of onset of regres-
sion was 3 yo after a period of normal development
for 10 patients. Early signs include gait ataxia,
hypotonia, speech and language difficulties and behav-
ioural and cognitive disorders. Most patients devel-
opped extrapyramidal and pyramidal signs. By early
teen age, all individuals have severe ID, loss of ambu-
lation and autonomy. No extra-central nervous system
manifestations were described so far. Although EEG is
abnormal in half the patients, epilepsy affected only
one third of the patients, and was reported as severe
in only one case [3]. Brain MRI shows predominant
supratentorial atrophy and T2 deep white matter
hyperintensities. Cerebellar atrophy is less remarkable
but reported in the majority of cases.
Discussion and Conclusions
After 5 years of diagnostic wandering, the finding of the spe-
cific, monoallelic de novo mutation c.628G>A (p.Glu210Lys)
in UBTF allowed us to recognise a newly-described neuro-
degenerative disease characterized by motor, behavioural,
and cognitive regression in early childhood.
Although the phenotype is nonspecific, it is in line
with the previous reported cases: regression begins in
pre-school years (median age 3 years) and is followed by
global neurological deterioration progressing until the
beginning of the second decade. Involvement is confined
to the central nervous system. Speech, language and
motor delay can be present prior to regression. Cogni-
tive and behavioural degradation follows no specific
Fig. 2 Brain MRI of the patient at different ages. Axial and coronal T2-weighted images. Supratentorial progressive cortical and subcortical
atrophy with ex vacuo ventriculomegaly and diffuse deep white matter hyperintensities. Note that MRI is already abnormal at 5yo, before onset
of regression. Cerebellar atrophy is only marginal. Basal ganglia, U-fibres, optic radiations, internal capsule and hippocampi were
globally preserved
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pattern. Autistic traits and aggressiveness were described
but absent in our case. Most patients develop cerebellar,
pyramidal, extrapyramidal signs and microcephaly over-
time. MRI findings are also consistent, showing cortico
sub cortical atrophy with T2 hypersignal involving white
matter and sometimes basal ganglia. Of note, despite a
high incidence of extrapyramidal signs, basal ganglia are
rarely abnormal.
Our case adds new insights on the natural history
and EEG features of these patients. First, phases of
neurological deterioration coincided with febrile and
afebrile infectious illnesses and were followed by in-
complete recovery. This finding was reported in only
one other case [3] but could have been underreported.
In both patients, it occurred in the first stage of the
disease. Fever and infection-triggered regression is
known in metabolic diseases such as mitochondrial
diseases or organic acidurias [8], but also in white
matter disorders such as vanishing white matter [9]
for which we found no evidence. Here, fever-induced
metabolic stress may have worsened the disease course
because the UBF protein has a major role in rDNA
transcription, and thus in ribosomal biogenesis, which
is a highly energy consuming process essential for cell
integrity [10]. Second, the EEG evolution was remark-
able. As in others neurodegenerative disorders, there
was a progressive and nonspecific slowdown of back-
ground activity. But, after the regression, we found
twice, at 7 and 8 years, a peculiar pattern of general-
ized semi-periodic slow waves (0.2 – 0.3 Hz) without
Fig. 3 EEG of the patient at different ages. a 5 yo, during drowsiness bilateral bursts of frontocentral spike-wave complexes, without clinical
correlate (b) 7yo, semi periodic delta waves without clinical manifestation; (c) 9yo, generalized spikes ad spike-waves complexes without clinical
correlation (during sleep). Background wake activity max 7-8Hz on a,b and c
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any clinical correlate. Although abnormal EEG activity
was reported in about half of the reported cases, only
one other case was detailed [3]. In both, interictal
epileptiform activity was characterized by anterior
epileptiform discharges [3]. Generalized periodic epi-
leptiform discharges with regression, suggests the
diagnosis of subacute sclerosing panencephalitis sec-
ondary to measles or rubella [11]. However, in the lat-
ter case these complexes are more regular, faster (1-
3Hz), sometimes intermingled with spikes and sharp
waves, can occur during sleep [11–13] and translate
into myoclonus. One can wonder whether this EEG
pattern may be specific of c.628 C>G UBTF-associated
neurodegeneration and whether it relates to a
particular stage of the disease. Data analysis failed to
reveal other variants that might have plausibly
accounted for the EEG abnormalities, either under a
recessive or a de novo dominant model [7]. Therefore,
we suggest that this might be part of the c.628 C>G
UBTF variant phenotype.
Even though UBTF c.628G>A -associated childhood
neurodegeneration has a consistent phenotype, no pathog-
nomonic clinical, imaging or biological features have been
identified up until now, and diagnosis was in our case only
achieved by NGS. Fever- or infection-triggered episodes of
regression with negative metabolic work up and a periodic
EEG pattern may be useful diagnostic cues that will have
to be confirmed with further case studies.
Table 1 Phenotype of patients with the UBTF c.628G>A variant
Edvardson et al [1]
N = 7
Toro et al [2]
N = 4
















3.5 [2.5 – 7] 2.7 [2 – 3] 1.3 – 2 5.8 3 [2 – 7]
DD prior to
regression
3 0 Mild speech delay Yes 5 (33%)




NA No 7/12 (58%)
Ataxia 3 4 1 (early on) 1 (early on) 9 (67%)
Extrapyramidal
signs
6 (3 dystonia, 2
rigidity,1 chorea)
3 (3 dystonia, 1
chorea)
















Dysarthria NA 4 NA Yes 5/5 (100%)
Swallowing
difficulties
NA 3 Yes (11yo) Yes (11 yo) 5/6 (83%)
Seizures/
Epilepsy
3 (onset 5, 14 and
15yo)
0 Yes (multiple types) 6 yo Yes (behavioural
arrest) 11 yo
5 (38%)
Outcome 7 non verbal with





steps, 4 severe ID





13 non verbal or severe language
impairment and severe ID (100%), 9




4 (no details) Abnormal
background rhythms
Diffuse β activity (5yo), sharp
waves (6yo), continuous
bilateral FT spikes, slow
background.
Yes (see text) 7 abnormal (53%)













13 cerebral atrophy and white
matter hs (100%), 10 cerebellar
atrophy (77%)
yo years-old, M male, F female, DD developmental delay, DTR deep tendon reflexes, ID intellectual disability, FT frontotemporal, hs hypersignal, NA not available
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